Avolynt is developing therapeutics for rare and metabolic disease. Avolynt's lead programs target Type 2 diabetes, NASH and Post Bariatric Hypoglycemia.
Company Location
3200 E. Highway 54, Suite 100
Research Triangle Park
NC
27709
P.O. Box 13888
Research Triangle Park
NC
27709
Phone
(919) 659-5677
County
Region
Company Details
Company type
Year founded
2015
Employment range in NC
US headquarters
North Carolina
Global headquarters
United States
Primary site activity
All company activities
Products on market
Remogliflozin, a novel inhibitor of SGLT2, was launched in May 2019.
Products under development
See website for pipeline.